注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Cue Biopharma Inc是一家處於發展階段的免疫治療公司。該公司致力於開髮用於選擇性調節與疾病相關的T細胞亞群,以治療癌症和自身免疫性疾病的生物製劑。其免疫腫瘤產品包括CUE-100框架和CUE-200框架;自身免疫性產品包括MHC I類項目和MHC II類項目。CUE-100框架限制了T細胞群的活性。CUE-200框架可實現有效的,長期的抗腫瘤T細胞反應。其自身免疫疾病療法保護健康細胞免受免疫攻擊。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Pamela Garzone | - | - | Director |
Steven C. Almo | 62 | 2015 | Co-Founder and Chairman of Scientific & Clinical Advisory Board |
Daniel R. Passeri | 62 | 2016 | CEO & Director |
Frank Morich | 70 | 2018 | Independent Chairman of the Board |
Hidde L. Ploegh | - | - | Member of Scientific & Clinical Advisory Board |
Abul K. Abbas | - | 2021 | Member of Scientific Advisory Board |
Michael Kalos | - | 2021 | Member of Scientific Advisory Board |
Kenneth J. Pienta | 63 | 2017 | Clinical Advisor |
David Baker | - | - | Member of Scientific & Clinical Advisory Board |
Rafi Ahmed | - | 2023 | Member of Scientific Advisory Board |
Pamela D. Garzone | 68 | 2023 | Independent Director |
Patrick Verheyen | 63 | 2023 | Independent Director |
Karolina Palucka | - | 2017 | Member of Scientific & Clinical Advisory Board |
Peter A. Kiener | 72 | 2016 | Independent Director |
Frederick W. Driscoll | 73 | 2018 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核